Advertisement

FDA Public Meeting on Patient-Focused Drug Development for Long COVID

Virtual Event Virtual Event

The U.S. Food and Drug Administration (FDA) is hosting a virtual public meeting  25 April 2023 on Patient-Focused Drug Development for Long COVID. This meeting will provide FDA the opportunity to obtain initial patient and patient representative input on the aspects of Long COVID, including how Long COVID affects their daily life, symptoms that matter

Test Development and Validation During the COVID-19 Public Health Emergency

Virtual Event Virtual Event

The U.S. Food and Drug Administration (FDA) will host a virtual town hall on 26 April 2023 for test developers to discuss the final guidances for the: Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency Transition Plan for Medical Devices Issued Emergency Use

Recombinant Protein-Based COVID-19 Vaccines Workshop

Virtual Event Virtual Event

The Biomedical Advanced Research and Development Authority (BARDA) and FDA will host a virtual workshop titled Recombinant Protein-Based COVID-19 Vaccines April 27, 2023, from 9:00 am EDT to 1:00 pm EDT. The goals of the workshop are to provide a forum for product sponsors to discuss progress and technical challenges in the manufacturing when changing

Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products

Virtual Event Virtual Event

The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) is hosting a virtual public listening meeting on 27 April 2023 to solicit input on methods and approaches (e.g., use of real-world evidence (RWE), registries) for capturing post approval safety and efficacy data for cell and gene therapy products. The rapid

Prioritizing Actions for Epidemic and Pandemic Preparedness

Virtual Event Virtual Event

The Prioritizing Actions for Epidemic and Pandemic Preparedness Virtual Symposium will be held 4 May and 18 May 2023. This first session will be held from 8:00am-12:00pm ET on 4 May 2023 and the second session from 8:00 am-12:00pm ET on 18 May 2023. The purpose of this symposium is to convene global health planning

ABRF 2023 Annual Meeting | Association of Biomolecular Resource Facilities

Sheraton Boston Hotel 39 Dalton Street, Boston, MA, United States

The Annual Meeting of the Association of Biomolecular Resource Facilities (ABRF 2023) will be held 7-10 May 2023 in Boston, Massachusetts. Highlighted topics and presentations include: Business Skills for Core Facility Directors, Managers and Administrators Advancing Single Cell in Core Laboratories Implementing Spatial Transcriptomics in Core Facilities Using R/R-Studio for reproducible data analysis and visualization

Collaborating on Culture in the New Era of Smarter Food Safety

Virtual Event Virtual Event

Live from the Food Safety Summit: Measure What You Treasure May 11, 2023, from 3:45 pm 5:00 pm ET The upcoming webinar will focus on the importance of assessing food safety culture in an organization. Guest speakers include: Donald A. Prater, DVM, Acting Director, Office of Food Policy and Response, FDA Conrad Choiniere, PhD, Director,

Prioritizing Actions for Epidemic and Pandemic Preparedness

Virtual Event Virtual Event

The Prioritizing Actions for Epidemic and Pandemic Preparedness Virtual Symposium will be held 18 May 2023. This is the second of two sessions. The purpose of this symposium is to convene global health planning stakeholders, including those in government and academia, and across health- and non-health sectors, to strengthen the capacity for evidence-based prioritization of global

VRBPAC Meeting on Pfizer’s ABRYSVO Respiratory Syncytial Virus Vaccine

Virtual Event Virtual Event

Vaccines and Related Biological Products Advisory Committee May 18, 2023 Meeting Announcement On 18 May 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0),